Annexin-V (PAP-I, lipocortin-V) acts as a potent anticoagulant in vitro by binding to negatively charged phospholipids with higher affinity than vitamin K-dependent proteins, with a K4 in the 10-10 M range. The purpose of the present study was to use annexin-V as a probe to assess the catalytic potential of phospholipids in pro-and anti-coagulant reactions in purified systems and at the surface of endothelial cells in culture after stimulation. Procoagulant tissue factor and anticoagulant thrombomodulin activities were compared by using specific two-stage amidolytic assays performed with purified proteins. Procoagulant activity was estimated by the generation of Factor Xa by the Factor VII(a)-tissue factor complex. Anticoagulant activity was estimated by the generation of activated protein C by either the thrombinthrombomodulin complex or Factor Xa. Annexin-V induced a decrease of 70% of thrombomodulin activity when thrombomodulin (5.4-214 nM) was reconstituted into phosphatidylcholine/phosphatidylserine (1:1, mol/mol) vesicles at 37.5 or 75 /tM-phospholipid concentration, the apparent K, being 0.5 ,uM at 75/sM-lipid. The saturating concentration of annexin-V was dependent on phospholipid concentration, but was independent of the phospholipid/thrombomodulin ratio. By contrast, when thrombomodulin was not reconstituted in vesicles, annexin-V had no effect. At 2 uM, annexin-V totally inhibited the generation of activated protein C by Factor Xa in the presence of 75 /sM-lipid, the saturating inhibitory concentration being dependent on phospholipid concentration. At 0.1 /LM, annexin-V totally inhibited tissuefactor activity present in crude brain thromboplastin. In the absence of stimulation, human endothelial cells in culture expressed significant thrombomodulin activity and no detectable tissue-factor activity. Basal thrombomodulin activity was only slightly inhibited (less than 15 %) by 0.5 /tM-annexin-V. Phorbol myristate acetate (PMA) induced the expression of tissue-factor activity and decreased thrombomodulin activity at the endothelial-cell surface. Annexin-V, at a concentration of 16 /Sm, caused an 80% decrease of tissue-factor activity induced by PMA at 10 ng/ml, whereas it inhibited thrombomodulin activity by only 15 % on the same stimulated cells. Our results confirm that annexin-V inhibits, in vitro, procoagulant tissue-factor activity and anticoagulant activities (activation of protein C by the thrombinthrombomodulin complex and by Factor Xa), through phospholipid-dependent mechanisms. They provide evidence that phospholipid exposure occurs during activation of human endothelial cells in culture by PMA and that this exposure could be involved in the expression of tissue-factor activity. However anionic phospholipids are of restricted accessibility in the vicinity of cellular tissue factor. The difference in the inhibition of thrombomodulin activity in purified systems and on endothelial cells suggests that the thrombomodulin conformation could be different under these two conditions and/or that vesicles do not reproduce the exact phospholipid environment of cellular thrombomodulin. The different extent of inhibition of tissue-factor and thrombomodulin activities on stimulated endothelial cells suggests that the cofactor environments differ for the optimal expression of these opposite cellular activities.
INTRODUCTION
. There is ample evidence that PtdSer exposure is of critical importance in cellular physiology In the absence of stimulation, phosphatidylserine (PtdSer) is (Zwaal & Hemker, 1982; Allen et al., 1988; Connor et al., 1989) . asymmetrically distributed between the two leaflets of blood and
In particular, it is involved in the regulation of haemostatic vascular cell membranes; it is almost exclusively located on the mechanisms by providing a procoagulant surface on activated cytoplasmic side of the plasma membrane. By contrast, after platelets, monocytes and endothelial cells where procoagulant stimulation, PtdSer becomes exposed on the outer side of the complexes can assemble and concentrate (Rodgers & Shuman, plasma membrane at a proportion depending on the nature of 1983; Tracy et al., 1985; Zwaal et al., 1986; Bach & Rifkin, 1990 ; the stimuli (Op den Kamp, 1979; Alberts et al., 1983; Zwaal et Hamilton et al., 1990; Komiyama et al., 1990) . PtdSer exposure al., 1977 PtdSer exposure al., , 1986 PtdSer exposure al., , 1989 . Different mechanisms responsible for the is also required in the anticoagulant protein C pathway, leading loss of the original asymmetry have been proposed (Seigneuret & to the inactivation of Factors Va and Vllla at the membrane Devaux, 1984; Sims et al., 1989; Hamilton et al., 1990; Verhallen, interface, which prevents them from participating in further amplification of thrombin generation. In this latter step, protein S acts as a cofactor of activated protein C (APC). The proteins assemble at the negatively charged phospholipid interface, thus accelerating the degradation of Factors Va and VIIIa (Solymoss et al., 1988) . Under physiological circumstances, the endothelial cell is basically non-thrombogenic, owing to its ability to maintain a delicate balance between procoagulant and anticoagulant tendencies. However, upon appropriate stimulation, it can acquire an active procoagulant character (Preissner, 1988; Stern et al., 1988) . The ability of endothelial cells to trigger or inhibit the generation of thrombin depends on the expression of two essential glycoproteins: an inducible one, tissue factor, and a constitutive one, thrombomodulin (TM). It has been proposed that PtdSer exposure is essential for the expression of tissuefactor activity (Drake et al., 1989; Bach & Rifkin, 1990; Komiyama et al., 1990) . By contrast, the involvement of negatively charged phospholipids in the activation of protein C at the surface of endothelial cells has not yet been clearly established, although they have been shown to enhance the activation of protein C by the purified thrombin-TM complex (Freyssinet et al., 1986 (Freyssinet et al., , 1988 Galvin et al., 1987) .
A better knowledge of the involvement of phospholipids in modulation of the thromboresistance of endothelium is necessary to elucidate the physiological and pharmacological regulation of haemostasis and thrombosis. PtdSer exposure has been extensively studied in platelets by using enzymic probes such as phospholipase A2 or chemical probes (Op den Kamp, 1979) . Recently, radiolabelled annexin-V was used as a non-degradative probe to provide evidence that phospholipid exposure is involved in the assembly of the prothrombinase complex at the platelet surface (Thiagarajan & Tait, 1990) .
Annexin-V, also referred to as PAP-I, VACa, IBC, PP4 or endonexin II (Funakoshi et al., 1987; Iwasaki et al., 1987; Reutelingsperger et al., 1988; Romish & Heimburger, 1990) is a member of the lipocortin/calpactin/annexin family (Crumpton & Dedman, 1990) . The physiological roles of these proteins are still poorly understood. There is evidence that annexin-V interacts with phospholipid vesicles (Tait & Gibson, 1990 ) and activated human platelets (Thiagarajan & Tait, 1990 ) in a Ca2+-dependent interaction with a Kd in the 10-10 M range. It can thus compete with vitamin K-dependent proteins for binding to procoagulant surfaces. Such competition was shown to be responsible for inhibition of the generation of thrombin in vitro (Funakoshi et al., 1987) , Factor IXa and Factor Xa (Kondo et al., 1987) . As yet, interference of annexin-V in the protein C anticoagulant pathway has not been described.
The purpose of the present study was to use annexin-V as a probe for phospholipids to assess their catalytic potential in proand anti-coagulant reactions in purified systems and at the surface of stimulated endothelial cells, all of human origin. Anticoagulant activity was evaluated by the generation of APC by either the thrombin-TM complex or Factor Xa. Procoagulant activity was measured by the generation of Factor Xa by the Factor VIIa-tissue-factor complex.
Annexin-V was shown to be involved in the anticoagulant mechanisms and to inhibit the generation of protein C at the surface of phospholipid vesicles. At the surface of endothelial cells, annexin-V interfered moderately in the anticoagulant mechanism, whereas it behaved as a potent inhibitor of tissuefactor activity, but at high concentration. (Zaccai, 1983) . Human placenta TM was extracted at pH 10.5 and purified by the method of Jakubowski et al. (1986) . Human protein C, thrombin [3000 National Institute of Health (NIH) units/mg], Factor X and Factor VII were purified from plasma as previously described (Freyssinet et al., 1988) . Purified human fibronectin was prepared as described by Ruoslahti et al. (1982) .
Mr values and absorption coefficients of proteins
Mr values and absorption coefficients at 280 nm cm, 280) used in calculating protein concentrations were as follows: Factor Xa, 45300 and 1.24 (Jackson, 1972) ; protein C, 58000 and 1.37 (Kisiel et al., 1976) ; APC, 54200 and 1.37 (Kisiel et al., 1976) ; thrombin, 37400 and 1.95 (Owen et al., 1974) ; TM, 74000 and 0.88 (Esmon et al., 1982) ; Factor VII, 53000 and 1.29 (Radcliffe & Nemerson, 1976) ; annexin-V, 35000 and 0.6 (Funakoshi et al., 1987) ; fibronectin, 440000 and 1.3 (Ruoslahti et al., 1982 Torbet & Freyssinet (1987) The effect of annexin-V on this activity was assessed at concentrations ranging between 0 and 7 ,uM. The incubation medium was 50 mM-Tris buffer, pH 7.5, containing 0.1 M-NaCl and 45 /tM-HSA (essentially fatty-acid-free) and incubation was for 15 min at 37 'C in a volume of 140 ,tl. Effect of annexin-V on the activation of Factor X by the Factor VII/thromboplastin complex. Thromboplastin from rabbit brain extract (0.1 g/l or 0.2 g/l) in 2 mM-CaCl2 was incubated for 15 min at 37 'C with 10 nM-Factor VII, 0.8 /tM-Factor X and annexin-V at concentrations ranging between 0 and 0.28 /M. The incubation medium was 50 mM-Tris buffer, pH 7.5, containing 0.1 M-NaCl and 45 ,M-HSA (essentially fatty-acid-free), the incubation volume was 140 /tl and the reaction was blocked by addition of S mM-EDTA. A 50 /tl portion of S2765 (0.5 mm final concn.) was then added, and the rate of hydrolysis was recorded at 405 nm for 2 min at 37 'C. Concentrations of Factor Xa formed were determined by reference to a standard curve established with known amounts of Factor Xa. It was verified that the generation of Factor Xa was linearly dependent on thromboplastin dilution under these conditions of excess Factor Xa and Factor VII.
Cell culture. Human saphenous-vein endothelial cells (HSVEC) were collected from fragments of saphenous vein obtained during coronary-by-pass surgery (Beretz et al., 1989) and cultured by a previously described method (Klein-Soyer et al., 1986) . The culture medium was RPMI/M 199 (1:1, v/v) containing 10 mmHepes, 2 mM-L-glutamine, antibiotics (100 units of penicillin and 100 jug of streptomycin/ml), fungizone (0.25 mg/ml) and 30 % (v/v) human serum. It was verified by a Limulus chromogenic assay (Coatest; Kabi Vitrum, M6lndal, Sweden) that all media and buffers had an endotoxin content of less than 0.02 ng/ml. Cells were frozen at the second passage and used in experiments at passage 3-10. For experiments, the cells were subcultured in 96-well plates precoated with purified human fibronectin at 0.5 mg/ml, at an initial cell density of 104 cells/cm2. Stimulation of cells. Assays were performed on confluent cell monolayers (3 x 104 cells/cm2), the culture medium being replaced 24 h before assays as described by Archipoff et al. (1991) . The cells were rinsed three times with 200 /tl of RPMI/M199 (1:1, v/v) and then incubated with 200 ,ul of RPMI/M199 containing 150 1sM-HSA and 16 nM-phorbol myristate acetate (PMA). After 4 h of incubation at 37 "C, the cells were rinsed three times in PBS. Tissue-factor and TM activities were then measured simultaneously, according to methods published by Archipoff et al. (1991) .
Effect of annexin-V on tissue-factor activity of HSVEC. For tissue-factor assay, 0-16 ,tM-annexin-V, 5 nm purified human Factor VII and 400 nm purified Factor X were added to each well. All dilutions were in RPMI/M 199 without Phenol Red containing 45 1sM-HSA and the final volume was 200 ,u. Removal of the supernatant from the cells was sufficient to block the activation of Factor Xa; this was verified by comparing the level of Factor Xa generated under these conditions with the level obtained after addition of excess EDTA. At the end of the incubation period, 20 min at 37 'C, 150 ,tl of the supernatant was removed and the amidolytic activity of generated Factor Xa was measured by the method of Archipoff et al. (1991) . Concen Incubation times were adjusted so that less than 20 % of the total protein substrate, either Factor X or protein C, was converted into its activated form. It was verified that the activity of controls with only one factor added (Factor VII, Factor X, thrombin or protein C) was always less than 2 % of the amidolytic activity measured under the same conditions with the complete assay system.
RESULTS

Effect of annexin-V on protein C activation by the thrombin-TM complex
When 108 nM-TM was reconstituted into PtdCho/ PtdSer vesicles (1: 1, mol/mol, 75 /uM-phospholipids), the rate of activation of 0.3 /M-protein C was enhanced 4-fold compared with the control without phospholipids, as shown in Fig. 1 (1.14+0.2nM-APC generated without lipids min-1; 4.5 + 0.6 nm min-' with phospholipids). These results were in agreement with those already published (Freyssinet et al., 1986) . Annexin-V, between 0 and 7 /uM, was responsible for a concentration-dependent limitation of this enhancement, due to the presence of phospholipids, whereas it did not affect the activation of protein C by the thrombin-TM complex in the absence of phospholipids (Fig. 1) . At saturating concentrations of annexin-V, inhibition reached a maximum of 70 + 2%, with TM reconstituted into vesicles composed of PtdCho/PtdSer (1: 1 molar ratio at a lipid concentration of 75 /M). For a lipid concentration of 75 /tM, half-maximum inhibition was reached at 0.5 /tMannexin-V (Fig. 1) ; for a lipid concentration of 37.5 /aM, halfmaximum inhibition was reached at 0.35 /uM annexin-V (results not shown). However, the half-maximum inhibition by annexin-V was not dependent on the phospholipid/TM molar ratio between 350 and 14000 (results not shown).
In order to characterize further the mechanism of inhibition, the substrate-dependence ofprotein C (0.1 ,UM, 0.2 /uM and 0.3 /LM) activation by the thrombin-TM complex (10 nm-thrombin and 108 nM-TM) was examined. These experiments were performed in the presence and absence of annexin-V (maximum 3 /uM) with PtdCho/PtdSer vesicles (1: 1, mol/mol, 75 /M-lipids). The Dixon plot of the data (Fig. 2) PMA (16 nM) caused the expression of tissue-factor activity resulting in 2+0.1 nM-Factor Xa generated/min per 104 cells. Factor X (400 nM) was activated by Factor VII (5 nM) at the surface of stimulated cells for 20 min at 37 'C. Each condition was assayed in sextuplate. Points correspond to the mean +S.E.M., and when no error bar is visible, the S.E.M. was less than 8 % of the mean value.
(1O nM) and rabbit brain thromboplastin (0.1 or 0.2 g/1). Inhibition was total above 0.05 /tM-annexin-V (Fig. 4) . Control activities without annexin-V were 0.37+0.1 nM-Factor Xa generated/min with 0.1 g of thromboplastin/litre and 1.05 + 0.04 nM-Factor Xa generated/min with 0.2 g of thromboplastin/litre.
Effect of annexin-V on protein C activation by thrombin at the surface of endothelial cells in culture Unstimulated endothelial cells expressed significant TM activity (23 + 0.7 pM-APC generated/min per 104 cells). PMA (16 nm for 4 h) caused a 60% decrease of this activity (9.5 + 0.6 pM-APC generated/min per 104 cells) (Archipoff et al., 1991) . Whereas annexin-V at 0.5 /LM inhibited by 15 % the activation of protein C at the surface of unstimulated cells, this concentration did not affect the activity of PMA-stimulated cells.
Annexin-V (O.12-16 /tM) caused a moderate concentration-dependent decrease in TM activity on PMA-stimulated cells, which also reached 15 % (results not shown).
Effect of annexin-V on Factor X activation by Factor VII at the surface of endothelial cells in culture Unstimulated HSVEC do not express tissue-factor activity. By contrast, addition of 16 nM-PMA for 4 h induced a strong tissuefactor activity at the surface of HSVEC, reaching 2 + 0.1 nmFactor Xa generated/min per 104 cells (Archipoff et al., 1991) . Annexin-V, between 0 and 16 UM, was responsible for a concentration-dependent decrease in tissue-factor activity at the surface of PMA-stimulated cells, 80 % inhibition being achieved at 16 ,uM-annexin-V (Fig. 5) .
Control activities without annexin-V were 1.08 + 0.07 nM-, 0.90 + 0.08 nm-and 0.91 + 0.03 nM-APC generated/min respectively at 37.5 /,M-, 75 /tM-and 150 ,#M-lipids.
Effect of annexin-V on Factor X activation by the Factor VII-thromboplastin complex Annexin-V, between 0 and 0.05 /tM, was responsible for a concentration-dependent inhibition of the activation of 800 nmFactor X by the complex formed between human Factor VII Vol. 282 
DISCUSSION
Previous studies have suggested that annexin-V is a potent inhibitor in vitro of phospholipid procoagulant mechanisms such as activation of prothrombin by Factor Xa (Reutelingsperger et al., 1985 (Reutelingsperger et al., , 1988 Funakoshi et al., 1987) and activation of Factor IX and Factor X by Factor VII and tissue factor (Kondo et al., 1987; Romish & Heimburger, 1990 Kd of 10-6-10-7 m for vitamin Kdependent proteins (Nelsestuen et at., 1978) ; hence it has been concluded that annexin-V interferes in the Ca2l-dependent assembly of procoagulant complexes on phospholipid surfaces containing phosphatidylserine (Funakoshi et al., 1987; Tait & Gibson, 1990) . The present study demonstrates that annexin-V can also be a potent inhibitor of the anticoagulant protein C pathway in vitro. Both types of protein C activation, by Factor Xa and by the thrombin-TM complex (Freyssinet etal., 1986 (Freyssinet etal., , 1988 Galvin etal., 1987) have been shown to be, at least in vitro, phospholipid-dependent. In addition, the extent of inhibition by annexin-V is dependent on both its concentration and that of phospholipids. This suggests that in purified systems the mechanism of inhibition of the protein C-dependent anticoagulant process by annexin-V can also be explained by competition for binding to phospholipids.
Confirmation has been obtained in another study where expression of the anticoagulant activity of activated protein C in the presence of protein S, phospholipids and activated platelets was observed to be'inhibited by annexin-V .
In the present study it could be confirmed that annexin-V is able to inhibit, in a concentration-dependent manner, activation of Factor X by the Factor VII-thromboplastin complex. Inhibition was total at saturating concentrations of annexin-V. These results confirm that annexin-V interacts with the acidic phospholipid component of the thromboplastin preparation (Kondo et al., 1987; Romish & Heimburger, 1990) .
It has been demonstrated that, in the presence of hirudin, the most potent known inhibitor of thrombin, human-protein C can be activated by human Factor Xa through a TM-independent mechanism, requiring only the presence of CaCI2 and phospholipid vesicles bearing a relatively high proportion of negative charges . Again, annexin-V behaved as a potent inhibitor in this system. The concentration of annexin-V which produced half-maximum inhibition was dependent on phospholipid concentration, suggesting that it is the rate-limiting factor. The catalytic potential of phospholipids in this anticoagulant process was assessed between 37.5 ,M and 150,uMlipids. This range is close to the equivalent phospholipid concentration of the physiological platelet count (60 ,UM equivalent to 300000 platelets/,ul; Zwaal et al., 1986) . However, the local phospholipid concentration at a site of platelet aggregation is expected to be the higher.
The sigmoidal shape of the curves (Fig. 3) The effects of annexin-V in vitro may be attributed to comparable requirements in phospholipids for the expression of these pro-and anti-coagulant activities. Thus annexin-V could be used as a probe to assess the catalytic potential of PtdSer in both activities. This hypothesis was further verified in a purified system by measuring the activation of protein C by the thrombin-thrombomodulin complex in the presence and absence of phospholipids. When thrombomodulin was reconstituted into vesicles having a net negative charge (PtdCho/PtdSer, 1:1, mol/mol), activation of protein C was enhanced 4-fold. Annexin-V suppressed the enhancing effect of phospholipids in a concentration-dependent manner, but had almost no effect on activation of protein C by thrombin in the presence of detergentsolubilized thrombomodulin or when thrombomodulin was reconstituted into 100% PtdCho vesicles (results not shown). Half-maximum inhibition was dependent on phospholipid concentration, but independent of the phospholipid-TM ratio. The inhibitory effect of annexin-V on the potentiation of al., 1988) and for annexin-V as an antagonist of the prothrombinase complex (Reutelingsperger etal., 1988) .
Tissue factor is generally considered to be the major cellular initiator of coagulation. However, purified detergent-solubilized tissue factor or tissue factor reconstituted into PtdCho vesicles has very low procoagulant activity (Bach etal., 1986) . Therefore phosphatidylserine exposed at the outer leaflet of the plasma membrane is believed to play an essential role in the modulation of tissue-factor activity (Carson & Ross, 1988; Drake etal., 1989; Gramzinski et al., 1989; Bach & Rifkin, 1990; Komiyama et al., 1990) . Under normal conditions, tissue factor is not exposed at the surface of cultured endothelial cells, whereas TM is constitutively expressed. Stimulation of the cells with PMA leads to the expression of tissue-factor activity, whereas TM activity is simultaneously slightly lowered (Archipoff et al., 1991) . In agreement with the promoting effect of PtdSer on tissue-factor activity, we observed that annexin-V could inhibit tissue-factor activity by 80% at the surface of endothelial cells after stimulation with PMA. These results provide evidence that PtdSer exposure occurs after stimulation of human endothelial cells in culture and that it could be involved in the expression of tissue-factor activity. However, the observation that 0.1 aMannexin-V was able to achieve 100% inhibition of isolated tissue factor, whereas 16 ,uM annexin-V was responsible for 80 % inhibition of cell-bound tissue factor, suggests restricted accessibility to the lipid patch on the cell surface. This is consistent with the view expressed by Forman & Nemerson (1984) that the tissue-factor-Factor VII(a) complex would preferentially cleave free Factor X instead of phospholipid-bound Factor X. By contrast, membrane phospholipids do not seem to be involved to a significant extent in the thrombin-TM interaction, since annexin-V inhibits TM activity by only 15 % either on stimulated or unstimulated cells. Furthermore, this inhibitory effect of annexin-V was comparable between resting cells or cells exposed to PMA, despite the fact that the stimulated cells should have an increased amount of PtdSer exposed on their outer membrane.
The differences in the inhibition of TM activity in purified systems and on endothelial cells suggest that the TM conformation could be different under these two circumstances and/or that vesicles do not represent the lipid environment of cellular TM (Galvin et al., 1987; Esmon & Esmon, 1988) . This discrepancy between purified systems and endothelial cells in culture could also be explained by differences in composition and physical organization of the PtdCho/PtdSer catalytic patch. The different influence of annexin-V on tissue-factor and TM activities at the surface of stimulated HSVEC also suggests that cofactor environments vary for the optimal expression of these opposite cellular activities.
Annexin-V should be of value as a probe for phospholipid structures bearing a proportion of anionic species. Another field of investigation would be the characterization of endothelial-cell particles that would disseminate a hypercoagulable tendency.
After disruption (Drake et al., 1989) or stimulation with endotoxin, tissue factor was found to be transported into the shed membrane of certain cells (Bona et al., 1987) . In addition, Hamilton et al. (1990) showed that assembly of the terminal complement protein complex C5b-9 on human endothelial cells induced membrane vesiculation. The resulting microparticles exposed binding sites for Factor Va and therefore supported prothrombinase activity. However, no significant change in TM status was observed during the short exposure (30 min) to C5b-9 (Hamilton et al., 1990) . Some mediators of the inflammatory response, such as tumour necrosis factor, interleukin-1 or endotoxin, were found to down-regulate TM activity at the surface of endothelial cells. The effect was significant only at 24 h after exposure, whereas tissue-factor activity was up-regulated as early as 2 h after contact (Moore et al., 1984; Stem et al., 1985; Nawroth et al., 1986; Archipoffet al., 1991) . Thus it is conceivable that the early inflammatory response could account for the disruption of the endothelial haemostatic balance reflected in opposite regulation of tissue factor and TM, with further impairment resulting from later vesiculation leading to the formation of microparticles with highly procoagulant phospholipid-dependent activity. Annexin-V could be a powerful tool to sort and characterize such particles under prothrombotic circumstances.
